Results of phase I/II trials with recombinant human interleukin-3.
Ganser
A
A
Department of Hematology, University of Frankfurt, Germany.
Ottmann
O G
OG
Seipelt
G
G
Eder
M
M
Geissler
G
G
Merget
R
R
Maurer
A
A
Falk
S
S
Lindemann
A
A
Herrmann
F
F
D000741:Anemia, Aplastic / Q000628:therapy; D000818:Animals; D001855:Bone Marrow Diseases / Q000628:therapy; D004353:Drug Evaluation, Preclinical; D006410:Hematopoiesis / Q000187:drug effects*; D006801:Humans; D007377:Interleukin-3 / Q000009:adverse effects / Q000627:therapeutic use*; D009190:Myelodysplastic Syndromes / Q000628:therapy; D009369:Neoplasms / Q000628:therapy; D011994:Recombinant Proteins / Q000009:adverse effects / Q000627:therapeutic use
D007377:Interleukin-3; D011994:Recombinant Proteins